Thyroid Dysfunction in Advanced Heart Failure Patients and Its Correlation with Amiodarone Therapy: A Two-Year Study
Agnieszka Kuczaj1,2, Szymon Warwas1, Anna Danel3
1Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.
Biomedicines
|March 28, 2024
Summary
Thyroid dysfunction is common in advanced heart failure patients, with amiodarone use a significant factor. However, this thyroid issue did not increase mortality in the study group.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Advanced heart failure frequently presents with ventricular arrhythmias, often requiring antiarrhythmic treatments.
- Amiodarone, a common antiarrhythmic, contains high iodine levels and can induce thyroid dysfunction.
- The prevalence and specific associations of amiodarone-induced thyroid dysfunction in end-stage heart failure are not well-established.
Purpose of the Study:
- To determine the prevalence and types of thyroid dysfunction in advanced heart failure patients.
- To investigate the association between amiodarone therapy and thyroid dysfunction in this cohort.
- To assess the impact of thyroid dysfunction on mortality in patients with advanced heart failure.
Main Methods:
- A two-year follow-up study of 200 advanced heart failure patients eligible for transplantation.
- Evaluation of thyroid function and correlation with amiodarone use.
- Analysis of patient data according to European Society of Cardiology guidelines.
Main Results:
- Thyroid dysfunction was observed in 61 patients (30.5%), more frequently in women.
- Hyperthyroidism (34 patients) and hypothyroidism (27 patients) were diagnosed.
- A significant correlation was found between amiodarone use and thyroid dysfunction, but not with increased mortality.
Conclusions:
- Thyroid dysfunction is prevalent in advanced heart failure, with amiodarone being a contributing factor.
- Thyroid dysfunction in this patient population does not appear to be associated with higher mortality rates.
- Further research is needed to optimize the management of thyroid dysfunction in refractory heart failure patients.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
988
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
988
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K